<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Plasma antithrombin III activity was studied in 22 patients with <z:hpo ids='HP_0012125'>prostatic cancer</z:hpo> who were on <z:chebi fb="0" ids="50114">estrogen</z:chebi> therapy </plain></SENT>
<SENT sid="1" pm="."><plain><z:mpath ids='MPATH_458'>Normal</z:mpath> plasma antithrombin III activity varies between 0.80 and 1.40 U. per ml </plain></SENT>
<SENT sid="2" pm="."><plain>A loading dose of 15 mg. <z:chebi fb="0" ids="41922">diethylstilbestrol</z:chebi> daily resulted in a marked decrease in plasma antithrombin III activity (mean 0.24 U. per ml.) </plain></SENT>
<SENT sid="3" pm="."><plain>Patients with the lower end of <z:mpath ids='MPATH_458'>normal</z:mpath> range of pre-treatment plasma antithrombin III activity may suffer acquired <z:hpo ids='HP_0001976'>antithrombin III deficiency</z:hpo> and, thus, a concomitantly increased risk of thromboembolic complications as a result of <z:chebi fb="0" ids="50114">estrogen</z:chebi> treatment </plain></SENT>
<SENT sid="4" pm="."><plain>Patients on maintenance therapy of approximately 1 mg. daily appear to have <z:mpath ids='MPATH_458'>normal</z:mpath> plasma antithrombin III levels </plain></SENT>
<SENT sid="5" pm="."><plain>The results obtained suggest that plasma antithrombin III activity should be monitored before and during <z:chebi fb="0" ids="50114">estrogen</z:chebi> therapy in patients with <z:hpo ids='HP_0012125'>prostatic cancer</z:hpo> </plain></SENT>
</text></document>